Skip to main content
Premium Trial:

Request an Annual Quote

La Jolla Institute Wins $12.6M from NIH for San Diego's First RNAi Screening Center

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — The La Jolla Institute for Allergy & Immunology has won a $12.6 million stimulus grant from NIH toward developing San Diego's first Center for RNAi screening, with the intent of hosting projects by researchers from throughout the region.

The center — one of five to be created nationally with NIH funding — will be housed at the La Jolla Institute's new Division of Signaling and Gene Expression. Mitchell Kronenberg, the institute's president and chief scientific officer, said in a statement that the center will be launched with four initial immunology-focused research projects examining how genes affect immune system function.

Kronenberg is co-lead investigator on the center grant along with Anjana Rao, whom the institute recruited from Harvard Medical School last year to lead the signaling and gene expression division. Three of the projects will be led by Kronenberg and Rao, along with scientists Sonia Sharma and Matthew Pipkin, who work with Rao.

The fourth project will be led by David Nemazee and Changchun Xiao, both from the Scripps Research Institute. Nemazee and Xiao will analyze how microRNAs regulate B lymphocytes, with an eye to better understanding diseases such as lupus and rheumatoid arthritis

According to the institute, the center will offer researchers help and advice about high-throughput screen design, tapping into Rao's expertise in the technology, in addition to molecular libraries and instrumentation.

"We recognize the power and groundbreaking capabilities of this technology and will use it to advance scientific knowledge toward new and more effective vaccines as well as potential new therapies for autoimmune diseases ranging from type 1 diabetes to rheumatoid arthritis," Kronenberg said in the statement.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.